Sotagliflozin might help patients with diabetes and chronic kidney disease who are hospitalized with heart failure avoid a readmission, study results suggest.
Whether successful treatment of depression reduces the risk for progression needs to be determined.
The NDA for finerenone is supported by data from the double-blind, placebo-controlled phase 3 FIDELIO-DKD trial.
The new KDIGO guideline highlights specific management differences by CKD severity.
Researchers assessed the risk for obstructive sleep apnea (OSA) among patients with type 2 diabetes and cardiovascular disease taking empagliflozin and further examined the effect of OSA on metabolic, cardiovascular, and renal outcomes.
Atrasentan outperformed both avosentan and bosentan for renoprotection in patients with type 2 diabetic kidney disease.
The 2020 ADA guideline update reflects evidence from recent major trials with cardiovascular and renal outcomes.
Dapagliflozin appears to preserve kidney function and improve survival in patients with chronic kidney disease whether or not they have type 2 diabetes.
In a trial, empagliflozin reduced the risks for heart failure hospitalization and renal outcomes in patients with heart failure with reduced ejection fraction.
The FDA concluded “the risk no longer meets the standard for a Boxed Warning.”